A private investment group that was founded by a family office has teams based in USA and Asia. The group is actively seeking new investments in the life sciences. The group invests broadly in therapeutics and digital health. The investment size will vary and typically it ranges from single to double digit millions. The group has no set number of allocations over the next 6-9 months.

In life sciences, the firm’s US team is looking for new investments in digital health and therapeutics. For therapeutics, the group is modality and indication agnostic. The group invests in both preclinical and clinical stage companies. The group is open to lead or syndicate with other investors.

The firm invests in privately-held life science companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm was founded in 2020 and is based in San Francisco, CA. The firm is expecting to close their first fund this year, targeting $100M. The firm is seeking to invest in Seed to Series A companies. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from Israel, Japan, Europe, Asia, etc.

Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech-enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.

The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor. If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Based in Boston and founded in 2006, a venture capital firm is currently investing from its fourth fund of $300 million closed in 2019. The firm typically is the lead or co-lead in the first institutional or Series A rounds in early-stage companies in the enterprise information technology (IT) space, including digital health. The firm’s equity investment size ranges from $3-7 million. The firm is most active on the US East Coast and would consider opportunities from across the US. The firm plans to make 5-7 new investments in the following year.

Within digital health, the firm is seeking systems, technologies, and services that support clinical delivery to improve outcomes and efficiency of clinical care. The firm is not interested in consumer-facing products, genomic analytics, or life sciences software – the focus is healthcare IT and services. The firm is looking for innovations that have demonstrated product-market fit in the form of recurring annual revenue of $1M or more. Pre-revenue companies may be considered if there is a strong fit with its investment thesis. When it comes to digital health investments, the firm often syndicates with strategic co-investors who understand the risks in the healthcare system, such as healthcare providers and payers.

The firm is looking for competent and experienced management teams with sector expertise. The firm brings in real-world experience, industry knowledge and networks, and company-building skills to its portfolio companies. The firm takes a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital firm was founded in 2012 and is based in San Diego, CA. The firm invests in a wide range of data-driven products that integrate AI, machine learning, and IoT. The firm is backed by a management team with a long, successful track record of building tech companies. The firm invests in the company’s early stages with an initial check size of $250 K with follow-on investments as the company matures, with equity and convertible loan as the preferred capital structures. The firm focuses on US-based companies, but may consider international companies with strongly innovative products that they can bring to the US market.

The firm will look at a range of verticals in the life sciences sector as long as there is a strong data-driven component in the company’s product. Sectors of interest include healthcare IT/digital health. The firm will not consider therapeutics or medical devices unless there is a heavy data component. The firm’s previous investments include an AI-driven image analysis platform for cancer detection, a computational DNA analysis platform for personalized cancer treatments, and a DNA amplification technology based on electric field-induced pH changes. The firm has their own AI Lab of top data scientists, so the company does not have to have the AI experts as long as they have the data, know how to get the data, and what information would be valuable to retrieve via machine learning applications.

The firm will work with companies backed by founders with deep domain expertise. The firm prefers deploying the venture studio model to help co-found companies, deploy their AI Lab experts, and will always take a board seat in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A private investment firm primarily invests in life sciences and disruptive technologies and is actively seeking new investment opportunities. The firm is most interested in USA-based companies, but is open to investing in other geographies given that the companies target the USA or EU markets.

The firm is most interested in therapeutics, and most of their portfolio companies have fallen in that sector thus far. The firm has reviewed medical device opportunities before, but has yet to make an investment in that space nor is that within the firm’s current focus. The firm steers away from digital health. Currently, the firm is most interested in vaccines, platform technologies, and reformulations and repurposed drugs (505(b)(2) or even ANDA regulatory pathway). For disease areas/indications, the firm is interested in infectious diseases, oncology/immuno-oncology, neurology, ophthalmology, and orphan diseases. The firm prefers to invest in clinical assets, and pre-IND assets are generally considered too early stage by the firm. For companies developing vaccines or in infectious diseases, the firm may consider earlier stage opportunities as the firm is most interested in these fields. The firm is also open to commercial stage opportunities.

The firm seeks to work with experienced management teams with a demonstrated track record of success. The firm generally co-invests alongside a syndicate and will not always seek a board seat. The firm does have strong strategic value-add, and seeks to work with their portfolio companies to help develop new R&D partnerships, commercial and licensing alliances, new drug development program collaborations, manufacturing, supply and distribution joint ventures, and more.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm based in the US is expecting to close their first fund this year. The firm is seeking to invest in Seed to Series A companies. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from Europe, Israel, and Asia.

Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.

The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A US fund invests in early-stage startups in many industries with a preference for healthcare and IT technology. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.